Ruthenium(II) polypyridyl complexes have been extensively studied for the past few decades
as promising anticancer agents. Despite the expected intravenous route of administration, the interaction
between Ru(II) polypyridyl compounds and serum proteins is not well characterized and vast majority
of the available literature data concerns determination of the binding constant. Ru-protein adducts
can modify the biological effects of the Ru complexes influencing their cytotoxic and antimicrobial
activity as well as introduce significant changes in their photophysical properties. More extensive research
on the interaction between serum proteins and Ru(II) polypyridyl complexes is important for
further development of Ru(II) polypyridyl compounds towards their application in anticancer therapy
and diagnostics and can open new opportunities for already developed complexes.
Keywords: Ruthenium(II) polypyridyl complexes, serum protein, albumin, binding, anticancer activity, RU-protien.
Rights & PermissionsPrintExport